Kodiak Sciences Inc.

DB:K27 Stock Report

Market Cap: €330.9m

Kodiak Sciences Valuation

Is K27 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of K27 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate K27's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate K27's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for K27?

Key metric: As K27 is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for K27. This is calculated by dividing K27's market cap by their current book value.
What is K27's PB Ratio?
PB Ratio1.9x
BookUS$185.37m
Market CapUS$350.18m

Price to Book Ratio vs Peers

How does K27's PB Ratio compare to its peers?

The above table shows the PB ratio for K27 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average1.9x
FYB Formycon
1.5x32.4%€882.0m
HPHA Heidelberg Pharma
3.1x-33.0%€111.9m
BIO3 Biotest
2x29.3%€1.3b
2INV 2invest
1xn/a€64.4m
K27 Kodiak Sciences
1.9x-7.0%€350.2m

Price-To-Book vs Peers: K27 is good value based on its Price-To-Book Ratio (1.9x) compared to the peer average (1.9x).

Price to Book Ratio vs Industry

How does K27's PB Ratio compare vs other companies in the DE Biotechs Industry?

3 CompaniesPrice / BookEstimated GrowthMarket Cap
V9Z Aceragen
0.1xn/aUS$3.12m
V9Z Aceragen
0.1xn/aUS$2.18m
O7P NeuBase Therapeutics
0.1xn/aUS$1.39m
No more companies available in this PB range
K27 1.9xIndustry Avg. 2.5xNo. of Companies3PB00.61.21.82.43+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: K27 is good value based on its Price-To-Book Ratio (1.9x) compared to the European Biotechs industry average (2.5x).

Price to Book Ratio vs Fair Ratio

What is K27's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

K27 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio1.9x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate K27's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst K27 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€6.17
€4.10
-33.5%
34.4%€5.68€1.89n/a6
Nov ’25€3.45
€2.46
-28.6%
15.7%€2.68€1.79n/a4
Oct ’25€2.29
€2.46
+7.3%
15.7%€2.68€1.79n/a4
Sep ’25€2.19
€2.43
+11.0%
17.7%€2.73€1.82n/a3
Aug ’25€2.64
€3.22
+21.8%
31.9%€4.60€1.84n/a4
Jul ’25€2.13
€3.22
+50.9%
31.9%€4.60€1.84n/a4
Jun ’25€2.74
€3.22
+17.5%
31.9%€4.60€1.84n/a4
May ’25€3.09
€3.92
+26.7%
45.2%€6.46€1.85n/a4
Apr ’25€5.46
€3.48
-36.4%
51.2%€6.49€1.85n/a4
Mar ’25€5.69
€2.44
-57.2%
24.7%€3.25€1.86n/a4
Feb ’25€3.67
€4.15
+13.3%
84.3%€11.07€1.85n/a5
Jan ’25€2.88
€4.00
+38.9%
87.0%€10.91€1.82n/a5
Dec ’24€2.17
€4.81
+121.7%
75.4%€11.00€1.83€6.174
Nov ’24€1.40
€3.80
+171.7%
46.8%€6.66€1.90€3.454
Oct ’24€1.63
€3.68
+126.3%
46.8%€6.44€1.84€2.294
Sep ’24€1.93
€3.68
+90.2%
46.8%€6.44€1.84€2.194
Aug ’24€2.47
€4.74
+92.0%
56.3%€9.12€1.82€2.645
Jul ’24€6.07
€10.31
+69.7%
54.4%€21.99€3.66€2.138
Jun ’24€5.46
€10.44
+91.2%
54.4%€22.28€3.71€2.748
May ’24€4.04
€10.19
+152.3%
54.4%€21.73€3.62€3.098
Apr ’24€5.40
€11.11
+105.7%
49.6%€22.69€4.73€5.468
Mar ’24€5.90
€10.94
+85.4%
49.6%€22.34€4.66€5.698
Feb ’24€7.30
€12.21
+67.3%
44.0%€23.08€4.81€3.6710
Jan ’24€6.35
€12.21
+92.3%
44.0%€23.08€4.81€2.8810
Dec ’23€6.80
€12.21
+79.6%
44.0%€23.08€4.81€2.1710

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

Regeneron Pharmaceuticals

US$80.7b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

RGO

US$720.00

7D

1.8%

1Y

-5.2%

Collegium Pharmaceutical

US$983.6m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

354

US$29.00

7D

0%

1Y

23.9%

Almirall

€1.9b

A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.

E2Z

€8.70

7D

4.9%

1Y

3.8%